EU/3/14/1241: Orphan designation for the treatment of Duchenne muscular dystrophy

Asp-Arg-Val-Tyr-Ile-His-Pro (Angiotensin 1-7)


This medicine is now known as Angiotensin 1-7.

On 19 February 2014, orphan designation (EU/3/14/1241) was granted by the European Commission to Gregory Fryer Associates Ltd, United Kingdom, for Asp-Arg-Val-Tyr-Ile-His-Pro for the treatment of Duchenne muscular dystrophy.

In December 2015, Gregory Fryer Associates Ltd changed name to Envigo Pharma Consulting Ltd.

The sponsorship was transferred to Envigo CRS S.A., Spain, in April 2019.

The sponsorship was transferred to Rapport Global Strategic Services Ireland Limited in January 2020.

Key facts

Active substance
Asp-Arg-Val-Tyr-Ile-His-Pro (Angiotensin 1-7)
Intended use
Treatment of Duchenne muscular dystrophy
Orphan designation status
EU designation number
Date of designation

Rapport Global Strategic Services Ireland Limited
22 Northumberland Road 
Dublin 4

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating